Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2021-12-29 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于股东部分股份解押及质押的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the partial release and new pledging of shares by the controlling shareholder of the company. It details the number of shares pledged and released, the pledgee institutions, and the purpose of the pledges (financing credit enhancement). It also includes background information on the controlling shareholder and confirms no material adverse impact on the company. There are no financial statements or comprehensive financial data presented, nor is this a report or presentation. The document is a regulatory announcement about share pledging activities by a major shareholder, which fits the category of Major Shareholding Notification (MRQ). The document length is about 3,000 characters, consistent with a typical announcement rather than a full report.
2021-12-29 Chinese
关于股东部分股份解押及质押的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the partial release and re-pledge of shares by its controlling shareholder, Haiwang Group. It details the number of shares pledged and released, the pledge purposes, and confirms no material impact on company operations or governance. The document includes tables of shareholding and pledge data, but does not contain financial statements or comprehensive financial analysis. It is a disclosure about share pledge activities, which relates to capital structure and financing activities. The document length is about 3,063 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, this document fits best under the category of Capital/Financing Update (CAP).
2021-12-15 Chinese
关于对外担保进展暨解除对外担保的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the progress and release of external guarantees provided by the company. It details the status of guarantees, repayment by a related party, and clarifies the current guarantee obligations. It does not contain financial statements, audit information, or detailed financial results. It is a regulatory announcement about guarantees, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2021-12-06 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shenzhen Haiwang Bioengineering Co., Ltd. regarding the approval of the company's 2021 third quarter report. It confirms the review and approval process but does not contain the actual financial data or the full report itself. The document length is short (615 characters) and it serves as an official announcement of the meeting resolution rather than the report. Therefore, it fits best under Regulatory Filings (RNS) as a formal announcement related to regulatory compliance and disclosure, not the full Interim/Quarterly Report (IR).
2021-10-27 Chinese
董事会决议公告
Report Publication Announcement Classification · 95% confidence The document is a formal announcement of the board of directors' meeting resolution approving the 2021 third quarter report. It references the report being published elsewhere (in newspapers and on a website) and does not contain the actual financial data or the report itself. The document length is short (548 characters), and it serves as a notice of the board meeting decision rather than the report. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) rather than the Interim/Quarterly Report (IR) itself.
2021-10-27 Chinese
2021年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳市海王生物工程股份有限公司 2021 年第三季度报告" which translates to "Shenzhen Haiwang Bioengineering Co., Ltd. 2021 Third Quarter Report." It contains detailed financial data including consolidated balance sheets, profit and loss statements, cash flow statements, and notes on financial adjustments. The document covers a quarterly period (third quarter of 2021) and includes substantive financial data and analysis. It is not a brief announcement or a certification letter but a comprehensive financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2021
2021-10-27 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.